Late Adverse Events After Implantation of Sirolimus-Eluting Stent and Bare-Metal Stent

Masahiro Natsuaki(Saga University), Takeshi Kimura(Kyoto University), Takeshi Aoyama(Hyogo Medical University), Mamoru Hayano(Hyogo Medical University), Ryuji Nohara, Hirofumi Kambara(Hyogo Medical University), Hisao Ogawa(Jikei University School of Medicine), Akinori Takizawa(Hyogo Medical University), Minoru Horie(Shiga University of Medical Science), Satoshi Shizuta(Kyoto University), Ryuichi Hattori(Hyogo Medical University), Mitsuru Abe(Kyoto Medical Center), Takashi Tamura(Japanese Red Cross Society Wakayama Medical Center), Manabu Shirotani(Hyogo Medical University), Junichi Tazaki(Hyogo Medical University), Eiji Shinoda(Hyogo Medical University), Yutaka Furukawa(Kobe City Medical Center General Hospital), Kenji Andò(Kokura Memorial Hospital), Hiroki Shiomi(Kyoto University), Satoru Suwa(Juntendo University Shizuoka Hospital), Moriaki Inoko(Hyogo Medical University), Kazuaki Mitsudo(Kurashiki Central Hospital), Katsuhisa Ishii(Hyogo Medical University), Kazushige Kadota(Kurashiki Central Hospital), Yoshiki Takatsu(Hyogo Medical University), Hisayoshi Fujiwara(Gifu University), Yoshihisa Nakagawa(Tenri Hospital), Takeshi Morimoto(Hyogo Medical University), Hiroshi Eizawa(Hyogo Medical University), Teruki Takeda(Hyogo Medical University), Shinji Miki(Hyogo Medical University), Masayuki Kato(Hyogo Medical University), Jong-Dae Lee(Hyogo Medical University), Masaru Tanaka(Osaka Red Cross Hospital), Mamoru Takahashi(Hyogo Medical University), Mitsuo Matsuda(Hyogo Medical University), Masakiyo Nobuyoshi(Kurume University), Toru Kita(Hyogo Medical University), Tomohisa Tada(Shizuoka General Hospital), Shuichi Hamasaki(Hyogo Medical University), Kyohei Yamaji(Kokura Memorial Hospital), Osamu Doi(Shizuoka General Hospital), Yoshihiro Kato(Hyogo Medical University)
Circulation Cardiovascular Interventions
February 19, 2014
10.1161/circinterventions.113.000987
Cited by 77

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
|JAMA|2019|830
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753